Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR's Bioprocessing Technology Institute (BTI), announced a new...
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...
WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an...
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing...
WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, ...
Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the...
WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced...
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing...
WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and...
WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The...
WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in...
WuXi STA - eine Tochtergesellschaft von WuXi AppTec - gab heute bekannt, dass es die Übernahme einer Produktionsstätte für Arzneimittel in Couvet,...
WuXi STA, une filiale de WuXi AppTec, a annoncé aujourd'hui qu'elle avait achevé l'acquisition d'une usine de fabrication de produits pharmaceutiques ...
WuXi STA, una subsidiaria de WuXi AppTec, anunció hoy que ha completado la adquisición de una planta de fabricación de productos farmacéuticos en...
WuXi STA – a subsidiary of WuXi AppTec – today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet,...
WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable...
WuXi AppTec, ein weltweit führender Anbieter von F&E- und produktionsunterstützenden Dienstleistungen in der pharmazeutischen, biotechnologischen und ...
WuXi AppTec, un fournisseur mondial de premier plan de services de R&D et d'aide à la fabrication dans les secteurs pharmaceutique, biotechnologique...
WuXi AppTec, un proveedor mundial líder dedicado a los servicios de habilitación de I+D y fabricación en las industrias farmacéutica, biotecnológica...
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device...
WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, ...
ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.